Please check your internet connection and try again.
# Diadzein + Genistein + Palmitoylethanolamide
## Overview
This is a combination product containing three active ingredients: Diadzein, Genistein, and Palmitoylethanolamide (PEA). Diadzein and Genistein are isoflavones found in soy. PEA is an endogenous fatty acid amide. The exact mechanism and clinical utility of this combination are not well-established in mainstream pharmacotherapy.
## Primary Indications
This combination is primarily marketed as a dietary supplement. It is often promoted for:
* Pain management, particularly neuropathic pain.
* Anti-inflammatory effects.
* Potentially as an adjunct in conditions involving mast cell activation.
**Note:** There is limited high-quality clinical trial data to support these indications in a conventional pharmaceutical context.
## Adult Dosing
Dosing for this combination is not standardized and varies significantly between products. Typical recommended doses from supplement manufacturers may range from:
* **Diadzein:** 100-200 mg daily.
* **Genistein:** 100-200 mg daily.
* **Palmitoylethanolamide (PEA):** 600-1200 mg daily, often divided into two or three doses.
**Uncertainty:** Specific dosing recommendations should be guided by the individual product's label and clinician judgment, as clinical trial data is insufficient for precise pharmaceutical dosing.
## Pediatric Dosing
There is no established or recommended pediatric dosing for this combination product. Its use in pediatric populations is not supported by clinical evidence.
## Dose Adjustments
No specific dose adjustments are recommended due to a lack of established dosing guidelines and pharmacokinetic data, particularly in organ dysfunction.
## Contraindications
* Hypersensitivity to any component of the product.
* Pregnancy and lactation (due to lack of safety data).
* Patients with hormone-sensitive cancers (e.g., breast, uterine, ovarian cancer, endometriosis, uterine fibroids) due to the phytoestrogenic properties of isoflavones, though the evidence for systemic effects from oral intake is debated.
## Adverse Effects
Adverse effects are generally mild and may include:
* **Gastrointestinal:** Nausea, bloating, diarrhea.
* **Allergic reactions:** Rash, itching.
* **Potential hormonal effects:** Due to isoflavones, though typically considered weak.
## Key Drug Interactions
* **Hormone therapies:** Potential additive or antagonistic effects with estrogen therapy or drugs like tamoxifen due to phytoestrogenic activity.
* **Anticoagulants/Antiplatelets:** Theoretical concern with high doses of isoflavones due to potential effects on platelet aggregation, though evidence is limited.
* **CYP450 substrates:** Isoflavones may have weak inhibitory or inducing effects on CYP enzymes, but significant interactions are unlikely at typical supplemental doses.
## Monitoring
* Monitor for symptom improvement (e.g., pain, inflammation).
* Observe for any adverse effects.
* For patients with a history of hormone-sensitive conditions, discuss use with their oncologist or gynecologist.
## Clinical Pearls
* This combination is typically available as a dietary supplement, not a prescription medication.
* The efficacy and safety profile are not as robustly defined as for FDA-approved pharmaceuticals.
* Patient counseling should emphasize that this is a supplement and not a substitute for conventional medical treatment.
* The role of PEA in pain and inflammation is an area of ongoing research.
***
**Disclaimer:** This information is intended for healthcare professionals. It is crucial to **verify current prescribing information, official guidelines, and consult relevant literature** before making clinical decisions, as drug information can change. This response is not a substitute for professional medical advice.
